KerryL(Massman)ReynoldsMD

Clinical Fellow in Medicine, Brigham and Women's Hospital

Dr. Reynolds is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
University of Missouri-Columbia School of MedicineClass of 2008

PubMed

67 citations
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.
Joerg Herrmann, Daniel Lenihan, Saro Armenian, Ana Barac, Anne Blaes
European Heart Journal. 2022-01-31
1212 citations
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein
Lancet. 2020-06-20
73 citations
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.
Shruti Gupta, Harish Seethapathy, Ian A. Strohbehn, Matthew J. Frigault, Elizabeth O'Donnell
American Journal of Kidney Diseases. 2020-07-01

Journal Articles

Cost-Effectiveness of Pembrolizumab plus Axitinib vs Nivolumab plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
Kerry (Massman) Reynolds, MD, JAMA Network Open

Lectures

Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trend...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Researchers Shed Light on Why Cancer Immunotherapies Sometimes Harm HeartNovember 8th, 2024
Mechanisms Behind Myocarditis in Cancer Patients Treated with Immune Checkpoint Inhibitors FoundNovember 6th, 2024
Study Reveals How Cancer Immunotherapy Leads to Deadly Form of Heart Inflammation in Some PatientsNovember 6th, 2024
Join now to see all